Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Lung Cancer ; (12): 66-77, 2023.
Artigo em Chinês | WPRIM | ID: wpr-971181

RESUMO

Immunotherapy has significantly improved clinical outcomes of non-small cell lung cancer (NSCLC), however, along with the popularization of immunotherapy, immune resistance has become an unavoidable problem. Immunotherapy can induce extensive cellular and molecular alterations in the tumor microenvironment. Considering the mechanisms of immune resistance are not yet fully understood and the efficacy of standard chemotherapy regimens is limited, more effective coping strategies based on resistance mechanisms are urgently needed. In this review, we intend to summarize the known mechanisms of immune resistance and feasible strategies, so as to provide a foundation for clinicians to develop more individualized and precise regimens and finally improve patients' prognosis.
.


Assuntos
Humanos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Prognóstico , Imunoterapia , Microambiente Tumoral
2.
Chinese Journal of Lung Cancer ; (12): 605-614, 2023.
Artigo em Chinês | WPRIM | ID: wpr-1010066

RESUMO

BACKGROUND@#Immune checkpoint inhibitors (ICIs) therapy lacks viable biomarkers for response and prognosis prediction. This study aimed to investigate the correlation of peripheral blood laboratory test results combined with lymphocyte subset ratios to the response and prognosis of immunotherapy in advanced lung cancer.@*METHODS@#Advanced lung cancer patients admitted to West China Hospital, Sichuan University from May 2021 to July 2023 were prospectively enrolled in this study. Clinical data and peripheral blood were collected before and after treatment and lymphocyte subset ratios were analyzed by flow cytometry. Logistic regression was used to identify factors correlated to ICIs treatment efficacy. Cox modeling was applied to explore the prognostic factors.@*RESULTS@#Logistic regression showed that the baseline level of transcription factor T cell factor 1 (TCF1)+CD8+ T cell ratio and peripheral white blood cell (WBC) count, lymphocyte percentage, cytokeratin 19 fragment (CYFRA21-1) after 1 cycle of ICIs treatment were the potential predictors for ICIs response (P<0.05). Cox regression analysis showed that the baseline level of TCF1+CD8+ T cell ratio (P=0.020) and peripheral WBC count after 1 cycle of ICIs treatment (P<0.001) were prognostic factors.@*CONCLUSIONS@#Patients with high baseline TCF1+CD8+ T cell ratio combined with low WBC counts and low CYFRA21-1 level after 1 cycle of ICIs treatment are more likely to benefit from ICIs therapy.


Assuntos
Humanos , Neoplasias Pulmonares/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Fator 1 de Transcrição de Linfócitos T/genética , Prognóstico , Linfócitos T CD8-Positivos , Imunoterapia
3.
Chinese Journal of Lung Cancer ; (12): 653-659, 2021.
Artigo em Chinês | WPRIM | ID: wpr-888590

RESUMO

Lung cancer is the malignancy with the highest mortality rate worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer severely affects the quality of life and prognosis of patients. Tumor-associated genetic testing is the basis for making precise treatment decisions. There are some risks of tissue biopsy, and it is difficult to sample repeatedly. Due to its non-invasive and can reflect the full profile of tumor gene characteristics, liquid biopsy is increasingly used in the diagnosis and treatment of lung cancer. Because of the extremely low DNA level of circulating tumor, the sensitivity and specificity of liquid biopsy based on blood samples are limited. Tumor cells is enriched in MPE. The detection of cell-free DNA, extracellular vesicles and microRNA in MPE will be helpful to the diagnose, treatment and assess prognosis of patients with lung cancer. This review aims to discuss the research progress of liquid biopsy based on MPE in the diagnosis and treatment of lung cancer patients.
.

4.
Chinese Journal of Medical Education Research ; (12): 558-562, 2020.
Artigo em Chinês | WPRIM | ID: wpr-865846

RESUMO

There are two methods of endoscopic teaching including traditional apprenticeship mode and simulation training. Although the apprenticeship model has some advantages in the docking of experience, there are many shortcomings. Virtual reality simulation training is learner-centered in endoscopic teaching, which is a safe and effective training method and an important supplement to the apprenticeship model. In the process of simulation training, paying attention to feedback, obtaining non-technical ability, dealing with emergencies in endoscopic operation and optimizing ergonomics are the directions of future research. This paper will briefly summarize the research progress of virtual reality simulation training in endoscope teaching.

5.
Chinese Journal of Lung Cancer ; (12): 118-124, 2019.
Artigo em Chinês | WPRIM | ID: wpr-775655

RESUMO

Lung cancer is the most commonly diagnosed cancer worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer seriously affect the patients' quality of life and prognosis. The management of MPE includes thoracentesis, pleurodesis, indwelling pleural catheters and drug perfusion in pleural cavity. Vascular endothelial growth factor (VEGF) and its receptor are a group of important ligands and receptors that affect angiogenesis. They are the main factors controlling angiogenesis, and they play an important role in the formation of MPE. Bevacizumab is a recombinant humanized VEGF monoclonal antibody, competitively binding to endogenous VEGF receptor. Bevacizumab can inhibit new blood vessel formation, reduce vascular permeability, prevent pleural effusion accumulation and slow the growth of cancers. This review aims to discuss the progress of bevacizumab in the treatment of MPE caused by non-small cell lung cancer (NSCLC), and explore the clinical application, efficacy, safety and future direction of bevacizumab.
.


Assuntos
Humanos , Antineoplásicos , Usos Terapêuticos , Antineoplásicos Imunológicos , Usos Terapêuticos , Carcinoma Pulmonar de Células não Pequenas , Patologia , Derrame Pleural Maligno , Tratamento Farmacológico , Neoplasias Pleurais , Tratamento Farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA